ROCEPHIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rocephin, and when can generic versions of Rocephin launch?
Rocephin is a drug marketed by Hoffmann La Roche and Roche and is included in five NDAs.
The generic ingredient in ROCEPHIN is ceftriaxone sodium; lidocaine. There are twenty-six drug master file entries for this compound. Additional details are available on the ceftriaxone sodium; lidocaine profile page.
Summary for ROCEPHIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 20 |
Patent Applications: | 7,994 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ROCEPHIN at DailyMed |
Recent Clinical Trials for ROCEPHIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Imperial College Healthcare NHS Trust | Phase 3 |
Singapore Clinical Research Institute | Phase 3 |
Royal Brisbane and Women's Hospital | Phase 3 |